2018 Annual Meeting

ASBrS 2018 Industry Symposia Content


Industry-supported symposia, which are made possible through marketing support, are offered each year during the annual meeting. The Society would like to give members and attendees who might not have been able to attend the symposia in Orlando access to the program content. Below are links that will take interested attendees to company websites where the handout materials/information and/or video/recording of the specific symposium will be available.    

NOTE: Industry satellite symposia are supported by specific companies and are supported through a marketing grant. They are not part of the official program of the ASBrS and are free to all registered attendees.

Disclaimer:  By clicking the posted links below, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

WEDNESDAY EVENING SYMPOSIUM

Wednesday, May 2

Ambry Genetics

Screening or Scalpel: How genetic testing for hereditary breast cancer can guide patient care

Program Highlights: The identification of hereditary breast cancer through germline genetic testing can have significant implications on medical management, including changes to screening, surgery, and therapeutic planning. As the trend towards multigene panels continues, our understanding of hereditary breast cancer continues to evolve. This symposium reviewed updated data from >90,000 patients with a personal and/or family history of breast cancer who have undergone multigene panel testing, and will discuss how genetic testing can help you find more answers for your patients and their family members.

For more information, visit www.ambrygenetics.com or contact Zach Jensen at zjenson@ambrygenetics.com.

NOTE: This satellite symposium is supported by Ambry Genetics, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.


THURSDAY EVENING SYMPOSIUM

Thursday, May 3

Genomic Health, Inc.

Why Big Clinical Trials Still Matter And What To Expect From TAILORx

Panel:

  • Larry Norton, MD, Medical Oncologist, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology
  • Memorial Sloan Kettering Cancer Institute
  • Terry Mamounas, MD MPH, FACS, Medical Director, Orlando Health UF Health Cancer Center
  • Steve Shak, MD, Co-Founder & Chief Scientific Officer, Genomic Health

For more information and to view the presentation, click here: https://genomichealth.box.com/s/c7vhltuqf0xrj11uyt94f4r3aleh517k
NOTE: This satellite symposium is supported by Genomic Health, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

Friday Evening Symposia

Friday, May 4
Programs:


Genentech, Inc.

Presurgical Considerations for Patients with Early Breast Cancer

Program Overview:

  • Exploration of current ASCO/CAP testing recommendations and the association between tumor biology and treatment decisions prior to surgery
  • Review of current surgical guidelines and considerations for patients who have received pre-operative systemic therapy
  • Interactive case-study-based discussions on the role of the multidisciplinary team

For more information, contact Barry Seeman at seeman.barry@gene.com.

NOTE: This satellite symposium is supported by Genentech, Inc., through a marketing grant. It is not part of the official program of the ASBrS.

back to Friday Evening Symposia


Invuity, Inc.

Next Generation Hidden Scar® Breast Cancer Surgery: Novel Technologies and Techniques that Prioritize Survivorship

Program Objective:   Discussion of new technologies and surgical techniques that are advancing and evolving Hidden Scar Breast Cancer Surgery.

This symposium discussed the advanced techniques, considerations, and enabling technologies in Hidden Scar Breast Cancer Surgery that prioritize both the oncologic and psychosocial outcomes essential for breast cancer survivorship. Faculty discussed how advanced photonics, enhanced energy and fluorescence imaging technologies impact surgical experience and clinical outcomes in the evolving landscape in Hidden Scar breast cancer surgical treatment by exploring how oncoplastic techniques and philosophies are advancing breast conservation surgery, and how breast and plastic surgeons are working together to push boundaries in nipple sparing mastectomy and pre-pectoral breast reconstruction.

To view a video of the symposium, click on the following link: https://www.youtube.com/watch?v=-NaY1C4tNds. For more information, please visit Invuity.com or contact Lindsey Fujita at lfujita@invuity.com.

NOTE: This satellite symposium is supported by Invuity, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Friday Evening Symposia


Saturday Breakfast Symposia

Saturday, May 5

Programs:

top of page


23andMe

Underutilized to Ubiquitous: Genetic Testing for Breast Cancer

Description of Program: Genetic testing for breast cancer risk is finally becoming commonplace and routine in the clinic. But in addition to the tests ordered, physicians are now given genetic information from new sources, such as direct-to-consumer (DTC) testing, whole genome sequencing of people, whole exome sequencing of tumors, and others. Dr. Kevin Hughes, Co-Director, MGH Avon Comprehensive Breast Evaluation Center, Associate Professor, Surgery, Harvard Medical School, and Medical Director, Bermuda Cancer Genetics and Risk Assessment Clinic discusses how to manage the results of traditional genetic testing as well as the results of genetic tests physicians did not order.

Learning Objectives:

  • Recognize known genes implicated in breast cancer including common mutations and their ethnic distribution.
  • Discuss with patients the significance of reports related to DTC and other types of genetic testing for breast cancer susceptibility including probabilistic information, limitations of test results, implications for other family members, options for cancer surveillance and prevention.

Click here to view Dr. Kevin Hughes’ presentation slides
Visit 23andMe website for clinicians to learn what’s included in 23andMe’s Health + Ancestry service and view sample reports.
Webinar: 23andMe's New FDA-Authorized BRCA1/BRCA2 (Selected Variants)* Report.

For more information, contact medical@23andme.com

NOTE: This satellite symposium is supported by 23andMe through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

*The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. The relevance of each report varies based on ethnicity.  Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. Our carrier status reports can be used to determine carrier status, but cannot determine if an individual has two copies of any genetic variant.  These carrier reports are not intended to tell an individual anything about risk for developing a disease in the future or anything about the health of a fetus, or newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk.   These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to diagnose disease, determine medical treatment or medical intervention including whether to take a medication or how much of a medication to take, or tell the user anything about their current state of health. Any diagnostic or treatment decisions must be based on confirmatory prescription testing and/or other information that you determine to be appropriate for your patient, such as additional clinical testing and other risk factors that may affect individual risk and health care.

Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up.  Results should be confirmed in a clinical setting before taking any medical action.
For important information and limitations regarding other genetic health risk reports, visit https://www.23andme.com/test-info/

Disclaimer:  By clicking the posted links, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


Albert Einstein College of Medicine

An Overview of an Anesthesiologist and Surgeon’s Effective Approach to Opioid Minimalization

Program Objectives:

  • Discuss the benefits of opioid-sparing treatment regimens in the care of patients experiencing postsurgical pain
  • Review the effects of liposomal bupivacaine in managing postoperative pain following breast surgical procedures
  • Analyze  enhanced recovery after surgery (ERAS) care pathways that are aimed at improving the patient experience with recovery while reducing health care costs and complications
  • Review the multimodal options utilized pre-op, inter-op and post-op in breast reconstruction surgery
  • Identify the surgical anatomy targeting PECS I, II, III, serratus, classic tap, subcostal and rectus sheath blocks

For more information, please contact Joyce Davis at joyce.davis@pacira.com. 

Note: This satellite symposium is supported by Pacira Pharmaceuticals through an educational grant provided to Albert Einstein College of Medicine. CME credits for this program will be provided by Albert Einstein College of Medicine. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent grant from Albert Einstein College of Medicine was provided to the ASBrS in order to offer this satellite symposium during the 19th Annual Meeting.)

back to Saturday Breakfast Symposia


Cianna Medical

Moving Beyond Wires: Oncoplastic Techniques with SCOUT®

Learn more about SAVI SCOUT®, the only non-radioactive, non-magnetic, wire-free breast localization system for lumpectomy or biopsy with no significant MRI artifact.
To view the presentation and additional information, click on the following link: https://www.ciannamedical.com/asbrs-presentation/

NOTE: This satellite symposium is supported by Cianna Medical, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


Focal Therapeutics, Inc.

Improving Outcomes with Oncoplastic Surgery: Techniques in "Reconstructive Lumpectomy"

Summary of program:
Topics included principles and practice of oncoplastic breast conserving surgery with specific attention focused on "reconstructive lumpectomy." Integration of the BioZorb implant was covered including tips on patient selection, surgical techniques, and other "pearls" on how to optimize patient outcomes. The latest findings from the BioZorb Registry were also presented.

For more information about the program, please visit http://www.focalrx.com/ or contact kmurray@focalrx.com.

NOTE: This satellite symposium is supported by Focal Therapeutics through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.

back to Saturday Breakfast Symposia


ImpediMed, Inc

SOZO® - L-Dex®, Bilateral, Heart Failure, and we’re just getting started...

Are hydration, bone density and tissue analysis important to monitor in your patients? Learn how ImpediMed is expanding and simplifying survivorship programs with our new SOZO® technology.

For more information, visit www.hellosozo.com or contact Nick George at 760-585-2081 or ngeorge@impedimed.com.
NOTE: This satellite symposium is supported by ImpediMed, Inc., through a marketing grant. It is not part of the official program of the ASBrS. This activity is free to all registered attendees.

Disclaimer:  By clicking the posted link, please understand you are leaving the ASBrS website and going to a website that is not operated by the Society.


back to Saturday Breakfast Symposia

top of page